121.20↑-2.75 (-2.22%)
03:45 PM,8th Dec 2023122.00↑-1.15 (-0.93%)
04:01 PM,8th Dec 2023BSE : 500259
NSE : LYKALABS
Sector : Health care
ISIN Code : INE933A01014
Last Updated: Dec 08 2023 | 04:01 PM IST
Market Cap (₹ Cr) | 401 |
Turnover (₹ Cr) | 0.05 |
Volume (Shares) | 40025 |
Face Value | 10 |
52-WK High | 155.90 |
52-WK High Date | 19 Jan 2023 |
52-WK Low | 88.50 |
52-WK Low Date | 23 May 2023 |
All Time High | 267.00 |
All Time High Date | 24 Dec 2021 |
All Time Low | 8.15 |
All Time Low Date | 21 Dec 2011 |
Initially manufacturing formulations Lyka Labs brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. '83. It also added a range of ayurvedic and animal health care products over the years. In 1990 it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson US; Airsep Corporation US; Coloplast Denmark; and Terumo Corporation Japan. Lyka Exports is the subsidiary of the company. The company offers a broad range of antibiotics used as life-savers and to treat minor infections. It has a fairly widespread product base with tropical steroids for skin disorders anti-cancer products cardio-vascular drugs and anti-inflammatory products. Lyka introduced in India cough lozenges containing dextromethorphan hydrobromide (DMR) favoured internationally as an effective and safe cough suppressant. Lyka has two formulations division and a bulk drugs division. It also set up additional manufacturing facilities for ointments. As part of its diversification it has invested in Relic Finance a company carrying on the business of finance and merchant banking.A GOI-recognised Export House it received the Certificate of Merit for its excellent export performance in 1993-94. In the same year it received an award from CHEMEXCIL for its outstanding performance.During 1997-98 the company's administrative office & plant at tarapur has been awarded ISO 9002 certification for its quality management system by SGS Yarsley International Certification Services Limited UK.The production carried out at Bombay has been shifted to Tarapur and Ankleshwar in the year 1999-2000 inorder to achieve economies of scale and better compliance. The company has assigned Trade Marks and transferred technical marketing know-how and allied rights pertaining to some of its products.
PARAMETER | VALUES |
---|---|
Market Cap (₹ Cr) | 401 |
EPS - TTM (₹) [S] | 0.00 |
P/E Ratio (X) [S] | 4.03 |
Face Value (₹) | 10 |
Latest Dividend (%) | - |
Latest Dividend Date | - |
Dividend Yield (%) | - |
Book Value Share (₹) [S] | 30.07 |
P/B Ratio (₹) [S] | 4.03 |
[*C] Consolidated [*S] Standalone |
Scheme Name ↑↓ | Amount Invested ( ₹ Cr ) ↑↓ | No Of Shares ↑↓ | Net Asset (%) ↑↓ |
---|---|---|---|
Quant Active Fund (G) | 8.67 | 841767 | 0.21 |
Quant Active Fund (IDCW) | 8.67 | 841767 | 0.21 |
Quant Active Fund - Direct (G) | 8.67 | 841767 | 0.21 |
Quant Active Fund - Direct (IDCW) | 8.67 | 841767 | 0.21 |
Date↑↓ | Broker↑↓ | Action↑↓ | Prices(Rs)↑↓ | Report |
---|---|---|---|---|
Data Not Found |
Today's Low/High | 119.80 125.00 |
Week Low/High | 119.80 136.00 |
Month Low/High | 105.75 144.00 |
Year Low/High | 88.50 156.00 |
All time Low/High | 8.46 267.00 |
Period | BSE | NSE | SENSEX | NIFTY |
---|---|---|---|---|
1 Week | -4.08% | -4.27% | 3.47 | 3.46% |
1 Month | 11.04% | 11.14% | 7.46 | 7.85% |
3 Month | 7.16% | 7.11% | 4.84 | 5.80% |
6 Month | 16.73% | 15.98% | 11.10 | 12.53% |
1 Year | -11.53% | -11.66% | 11.59 | 12.68% |
3 Year | 430.42% | 430.42% | 53.10 | 56.57% |
Chairman & MD & CEO : KUNAL NARENDRA GANDHI
Non-Exec. & Independent Dir. : Sandeep P Parikh
Executive Director & CFO : Yogesh B Shah
Non-Exec. & Independent Dir. : Dhara P. Shah
Company Sec. & Compli. Officer : Kishore P Shah
Independent Director : Babulal Jain
Director : Prashant Godha
Director : Shashil Mendonsa
Registered Office: 4801/B & 4802/A, GIDC Industrial Estate,Ankleshwar,Gujarat-393002 Ph: 91-02646-221422/220549